{"id":27531,"date":"2026-04-15T14:09:24","date_gmt":"2026-04-15T14:09:24","guid":{"rendered":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/multiple-sclerosis-could-roches-bestselling-drug-ocrevus-be-doing-more-harm-than-good-in-women-with-primary-progressive-ms\/"},"modified":"2026-04-21T10:39:38","modified_gmt":"2026-04-21T10:39:38","slug":"multiple-sclerosis-could-roches-bestselling-drug-ocrevus-be-doing-more-harm-than-good-in-women-with-primary-progressive-ms","status":"publish","type":"the-bmj-article","link":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/multiple-sclerosis-could-roches-bestselling-drug-ocrevus-be-doing-more-harm-than-good-in-women-with-primary-progressive-ms\/","title":{"rendered":"MS: Could Roche\u2019s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS?"},"featured_media":0,"template":"","categories":[],"tags":[],"content_type":[32],"editorial_panel":[],"channel_page":[43],"class_list":["post-27531","the-bmj-article","type-the-bmj-article","status-publish","hentry","article-type-news","channel-page-news"],"aioseo_notices":[],"meta_box":{"the_bmj_article-url":"\/content\/393\/bmj.s666","the_bmj_article-description":"This investigation explores how an $80 000 a year drug was approved despite concerns ","the_bmj_article-the_bmj_article_image":[{"width":150,"height":150,"file":"2026\/04\/Roche_building_2WCJ68G-copy.jpg","filesize":236337,"sizes":{"medium":{"file":"Roche_building_2WCJ68G-copy-300x194.jpg","width":300,"height":194,"mime-type":"image\/jpeg","filesize":38799,"url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2026\/04\/Roche_building_2WCJ68G-copy-300x194.jpg"},"thumbnail":{"file":"Roche_building_2WCJ68G-copy-150x150.jpg","width":150,"height":150,"mime-type":"image\/jpeg","filesize":26063,"url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2026\/04\/Roche_building_2WCJ68G-copy-150x150.jpg"}},"image_meta":{"aperture":"0","credit":"Alamy Stock Photo","camera":"","caption":"2WCJ68G Sign and logo on the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group F. Hoffmann-La Roche","created_timestamp":"1705276800","copyright":"Credit: HJBC \/ Alamy Stock Photo","focal_length":"0","iso":"0","shutter_speed":"0","title":"Sign and logo on the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group F. Hoffmann-La Roche","orientation":"1","keywords":["sign","logo","roche","la","roche","hoffmann","headquarters","france","pharmaceutical","brand","boulogne","billancourt","biotech","biotechnology","blue","building","business","care","chemistry","close-up","company","corporate","corporation","development","diabetes","diagnostics","european","exterior","facade","finance","group","health","innovation","institute","laboratory","medical","medicine","medicines","no","people","office","oncology","pharma","pharmacy","research","science","scientific","street","switzerland","symbol","therapeutic","treatment"]},"ID":"27526","name":"Roche_building_2WCJ68G-copy.jpg","path":"\/dom34810\/wp-content\/uploads\/sites\/4\/2026\/04\/Roche_building_2WCJ68G-copy.jpg","url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2026\/04\/Roche_building_2WCJ68G-copy-150x150.jpg","full_url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2026\/04\/Roche_building_2WCJ68G-copy.jpg","title":"Sign and logo on the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group F. Hoffmann-La Roche","caption":"2WCJ68G Sign and logo on the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group F. Hoffmann-La Roche","description":"","alt":"Roche's building","srcset":false}],"the_bmj_article-related_articles":[],"the_bmj_article-journal_name":""},"head_tags":[{"tag":"title","content":"MS: Could Roche\u2019s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS? | The BMJ"},{"tag":"meta","attributes":{"name":"robots","content":"max-image-preview:large"}},{"tag":"link","attributes":{"rel":"canonical","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/multiple-sclerosis-could-roches-bestselling-drug-ocrevus-be-doing-more-harm-than-good-in-women-with-primary-progressive-ms\/"}},{"tag":"meta","attributes":{"name":"generator","content":"All in One SEO (AIOSEO) 4.9.7.2"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ | The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:title","content":"MS: Could Roche\u2019s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS? | The BMJ"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/multiple-sclerosis-could-roches-bestselling-drug-ocrevus-be-doing-more-harm-than-good-in-women-with-primary-progressive-ms\/"}},{"tag":"meta","attributes":{"property":"article:published_time","content":"2026-04-15T14:09:24+00:00"}},{"tag":"meta","attributes":{"property":"article:modified_time","content":"2026-04-21T10:39:38+00:00"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"MS: Could Roche\u2019s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS? | The BMJ"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Comments Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/comments\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (JSON)","type":"application\/json+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Fmultiple-sclerosis-could-roches-bestselling-drug-ocrevus-be-doing-more-harm-than-good-in-women-with-primary-progressive-ms%2F"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (XML)","type":"text\/xml+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Fmultiple-sclerosis-could-roches-bestselling-drug-ocrevus-be-doing-more-harm-than-good-in-women-with-primary-progressive-ms%2F&format=xml"}},{"tag":"link","attributes":{"rel":"https:\/\/api.w.org\/","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"JSON","type":"application\/json","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/27531"}},{"tag":"link","attributes":{"rel":"EditURI","type":"application\/rsd+xml","title":"RSD","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/xmlrpc.php?rsd"}},{"tag":"meta","attributes":{"name":"generator","content":"WordPress 6.9.4"}},{"tag":"link","attributes":{"rel":"shortlink","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/?p=27531"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ"}},{"tag":"meta","attributes":{"property":"og:title","content":"MS: Could Roche\u2019s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS?"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/multiple-sclerosis-could-roches-bestselling-drug-ocrevus-be-doing-more-harm-than-good-in-women-with-primary-progressive-ms\/"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"MS: Could Roche\u2019s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS?"}},{"tag":"meta","attributes":{"name":"twitter:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/multiple-sclerosis-could-roches-bestselling-drug-ocrevus-be-doing-more-harm-than-good-in-women-with-primary-progressive-ms\/"}},{"tag":"meta","attributes":{"name":"twitter:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary_large_image"}}],"_links":{"self":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/27531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article"}],"about":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"type":[{"embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"wp:attachment":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/media?parent=27531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/categories?post=27531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/tags?post=27531"},{"taxonomy":"article-type","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/content_type?post=27531"},{"taxonomy":"editorial-panel","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/editorial_panel?post=27531"},{"taxonomy":"channel-page","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/channel_page?post=27531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}